In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, reduced lesion growth and size while slowing ellipsoid zone loss, according to a press release from Ocugen.“This outcome repre…
WASHINGTON–(BUSINESS WIRE)–MightyMeals CEO and Executive Chef Stefano Marzano recently reunited with Dr. Marijean Miller of Children’s National Hospital, the ophthalmologist who treated him from infancy through age 18 after he was born blind—a moment…
Medical offices are sick and tired of faxing, and federal officials agree. But modernization won’t be easy. Medscape Medical News
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced final 20-week study completion data from its randomized, head-to-head Phase 1…
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial-stage ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that YUVEZZI™ (carbachol an…
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The…